Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azole-echinocandin combination therapy for invasive aspergillosis
NCT04876716Phase 3Terminated
- Sponsor
- Erasmus MC
- Start
- May 2021
- Primary completion
- May 2024
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of anidulafungin in invasive aspergillosis (IA) (2 arms), sponsored by Erasmus MC. Primary endpoint: Overall survival 42 days. Started May 2021; status: terminated.
02
Drugs
anidulafungin
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT04876716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04876716.